Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.

ABSTRACT:

Background and purpose

c-Met (also known as MET) protein is encoded by the MET proto-oncogene. In non-small cell lung cancer (NSCLC), c-Met protein overexpression (OE) drives tumorigenesis and is a therapeutic target, given recent US Food and Drug Administration approval of telisotuzumab vedotin-tllv. This retrospective analysis of tumor samples and clinical data from real-world patients with non-squamous NSCLC characterized the prevalence of c-Met protein OE, its association with messenger ribonucleic acid (mRNA) expression, MET gene amplification, programmed-death ligand 1 (PD-L1) expression, and its impact on prognosis.

Patients and methods

A patient cohort was selected for manual abstraction of clinical data from electronic health records. Patients were selected based on

SUBMITTER: Bar J 

PROVIDER: S-EPMC12640106 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature